Objective: Brain metastases (BMs) from biliary tract cancer (BTC) are extremely rare. The aim of our study was to report the incidence of BMs in patients with BTC. Methods: We retrospectively analyzed a series of 450 patients with BTC. Presence of brain lesions was investigated only when symptoms were evident. Cumulative incidence, median overall survival (OS) from detection of BMs, median OS from cancer diagnosis, and median time from cancer diagnosis to detection of BMs were evaluated. Results: In our series, 6 patients developed BMs with an incidence of about 1.4%. Median OS from detection of BMs and from cancer diagnosis was, respectively, 3.7 (0.9-17.8) and 23 (9.9-57.6) months. Median time between cancer diagnosis and detection of BMs was 13.6 (7.3-52.8) months. Moreover, we observed a significant association between BMs and bone metastases (particularly vertebral lesions). Discussion: Despite the retrospective design, this is the first study evaluating the incidence of BMs among patients with BTC in Western countries. BMs from BTC remain atypical, although their incidence is probably a little higher than previously assumed. Patients with BMs had poor prognosis. Unpredictably, bone involvement occurred in 5 out of 6 patients.

Keywords:
Cholangiocarcinoma, Biliary tract cancers, Brain metastases, Metastasis, Bone metastases
1.
Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C, et al: Optimum chemotherapy for the management of advanced biliary tract cancer. World J Gastroenterol 2015;21:4121-4125.
2.
Noel MS, Hezel AF: New and emerging treatment options for biliary tract cancer. Onco Targets Ther 2013;6:1545-1552.
3.
Sasaki T, Isayama H, Nakai Y, Koike K: Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med 2013;28:515-524.
4.
Park JO, Oh D-Y, Hsu C, Chen J-S, Chen L-T, Orlando M, et al: Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review. Cancer Res Treat 2015;47:343-361.
5.
Brandi G, Venturi M, Pantaleo MA, Ercolani G, GICO: Cholangiocarcinoma: current opinion on clinical practice diagnostic and therapeutic algorithms: a review of the literature and a long-standing experience of a referral center. Dig Liver Dis 2016;48:231-241.
6.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
7.
Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, et al: Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer 2014;110:2165-2169.
8.
Eckel F, Brunner T, Jelic S, ESMO Guidelines Working Group: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(suppl 6):vi40-vi44.
9.
Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, et al: Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients. Oncologist 2016;21:600-607.
10.
Edeline J, Bonnetain F, Phelip JM, Watelet J, Hammel P, Joly J-P, et al: Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol 2017;35(no. 4_suppl):225.
11.
Horgan AM, Amir E, Walter T, Knox JJ: Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934-1940.
12.
de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
13.
Brandi G, Di Girolamo S, Farioli A, de Rosa F, Curti S, Pinna AD, et al: Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. Cancer Causes Control 2013;24:911-918.
14.
Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A: Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 2012;32:4655-4662.
15.
Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-2705.
16.
Go PH, Klaassen Z, Meadows MC, Chamberlain RS: Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011;117:3630-3640.
17.
Farnell GF, Buckner JC, Cascino TL, O'Connell MJ, Schomberg PJ, Suman V: Brain metastases from colorectal carcinoma. The long term survivors. Cancer 1996;78:711-716.
18.
Bartelt S, Momm F, Weissenberger C, Lutterbach J: Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. World J Gastroenterol 2004;10:3345-3348.
19.
Chindaprasirt J, Sookprasert A, Sawanyawisuth K, Limpawattana P, Tiamkao S: Brain metastases from cholangiocarcinoma: a first case series in Thailand. Asian Pac J Cancer Prev 2012;13:1995-1997.
20.
William BM, Grem JL: Brain metastasis and leptomeningeal carcinomatosis in a patient with cholangiocarcinoma. Gastrointest Cancer Res 2011;4:144-145.
21.
Mirrakhimov AE, Nwankwo N, Zdunek T, Bucher N: Cholangiocarcinoma and brain lesions: an extremely rare finding. BMJ Case Rep 2013, DOI: 10.1136/bcr-2013-009235.
22.
Kilbourn KJ, Aferzon J, Menon M: Isolated brain metastasis in cholangiocarcinoma: a case report and review of literature. Conn Med 2014;78:161-162.
23.
Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S: Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget 2015;6:14744-14753.
24.
Gril B, Evans L, Palmieri D, Steeg PS: Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer 2010;46:1204-1210.
25.
Gavrilovic IT, Posner JB: Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005;75:5-14.
26.
Tobinick E, Vega CP: The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed 2006;8:53.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.